Compare Quest Diagnostics Inc (DGX) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Marathon Petroleum Corp — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Marathon Petroleum Corp trades at $348 (market cap $94.48B). The key difference: Marathon Petroleum Corp is far larger — about 3.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | MPC | |
|---|---|---|
Market Cap | $26.21B | $94.48B |
Sector | Health | Energy |
52-Week High | $238.50 | $336.42 |
52-Week Low | $173.49 | $159.11 |
Enterprise Value | $31.97B | $121.00B |
Dividend Yield | 1.45% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Marathon Petroleum (MPC) trades at $345.68, up 7.92% over 24 hours, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with a P/E of 11.67 and ROE of 47.9%, supported by recent earnings beats including Q2 2026 EPS of $17.73 versus $14.27 expected. Refining margins remain elevated due to global supply constraints, driving revenue growth projections to $153.6B for 2026.
MPC presents a compelling investment case with strong cash flow generation and shareholder returns via dividends and buybacks. Key risks include exposure to volatile energy markets and geopolitical factors affecting refining margins. Wall Street maintains strong bullish consensus with 76% buy ratings and $332.70 price target, though current price exceeds consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
